Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
May 2021—Roche launched the Cobas SARS-CoV-2 Variant Set 1 Test to detect and differentiate mutations found in variants that originated in the U.K. (B.1.1.7), South Africa (B.1.351), and Brazil (P.1). This research use only laboratory test can be used to help scientists track mutation prevalence and to assess potential impact on diagnostics, vaccines, and therapeutics.
May 2021—The FDA granted emergency use authorization for Abbott’s Alinity m Resp-4-Plex molecular assay, which detects and differentiates SARS-CoV-2, influenza A and B, and respiratory syncytial virus in one test. The test is CE marked and available in countries outside the U.S.
May 2021—Promega Corp. released its XpressAmp Direct Amplification Reagents. The product contains components for performing extraction-free preparation of viral samples for PCR-based amplification using commonly available PCR reagents from samples collected by nasopharyngeal swab in universal or viral transport medium. The reagents allow the user to perform direct amplification analysis in RT-qPCR following a 10-minute, room-temperature incubation.
May 2021—Quidel received FDA emergency use authorization allowing the company to market its QuickVue At-Home OTC COVID-19 Test for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 from individuals with or without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over two or three days, with at least 24 hours, but no more than 36 hours, between tests. This test is authorized for nonprescription home use with self-collected direct anterior nares specimens from individuals aged 14 years and older or with adult-collected anterior NS samples from individuals who are two years old or older.
May 2021—Adaptive Biotechnologies Corp. launched its T-Detect COVID, a clinical T-cell–based test to identify people who have evidence of a cellular immune response against SARS-CoV-2. It uses Adaptive’s immunoSEQ technology to sequence T-cell receptors from a blood sample and identifies TCRs that the company has mapped for recognition of SARS-CoV-2 antigens.
May 2021—Qiagen announced the global launch of the CE-IVD-marked QIAcube Connect MDx, a flexible platform for automated sample processing available now to molecular diagnostic laboratories in the U.S., Canada, the European Union, and other markets worldwide.
May 2021—Seegene announced it has submitted its Allplex SARS-CoV-2/FluA/FluB/RSV Assay to the FDA for emergency use authorization.
May 2021—Thermo Fisher Scientific launched its Applied Biosystems TaqMan SARS-CoV-2 Mutation Panel, with a customizable menu of 22 verified real-time PCR assays for identification of SARS-CoV-2 mutations. The assays enable surveillance of variants that cause COVID-19 infection in specific regions globally and allow laboratories to choose which mutations to track.
April 2021—BD announced FDA emergency use authorization for its BD SARS-CoV-2/Flu assay, a molecular diagnostic test for SARS-CoV-2 and influenza A and B that provides results in two to three hours. The test also has been CE marked to the IVD directive.
April 2021—Diazyme received FDA emergency use authorization for its Semi-Quantitative DZ-Lite SARS-CoV-2 IgG CLIA test, which runs on the DZ-Lite 3000 Plus chemiluminescence analyzer. The FDA granted Diazyme an EUA for its qualitative DZ-Lite SARS-CoV-2 IgG CLIA test in July and has now authorized the Diazyme IgG assay to be used as a semiquantitative test.
